A glucokinase activator
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

PF-04937319 (hydrate)

Item No. 30926

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N,N-dimethyl-5-[[2-methyl6-[[5-methyl-2-pyrazinyl)amino]carbonyl]-4-benzofuranyl]oxy]-2-pyrimidinecarboxamide, hydrate
Molecular Formula
C22H20N6O4 • XH2O
Formula Weight
432.4
Purity
≥98%
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMSO: 100 mM
SMILES
CN(C)C(C1=NC=C(OC2=C(C=C(C)O3)C3=CC(C(NC4=NC=C(C)N=C4)=O)=C2)C=N1)=O.O
InChi Code
InChI=1S/C22H20N6O4.H2O/c1-12-8-24-19(11-23-12)27-21(29)14-6-17-16(5-13(2)31-17)18(7-14)32-15-9-25-20(26-10-15)22(30)28(3)4;/h5-11H,1-4H3,(H,24,27,29);1H2
InChi Key
TZHWWOYEMHALRI-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $41

    Add

    5 mg

    $119

    Add

    10 mg

    $215

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    PF-04937319 is an activator of glucokinase (EC50s = 174, 407, and 269 nM for the recombinant human, rat, and dog enzymes, respectively).1 It increases glucose-induced insulin secretion in isolated rat islets when used at concentrations of 4 and 12 µM.2 PF-04937319 (3-100 mg/kg) reduces postprandial plasma glucose levels in rats.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Petterson, J.C., Litchfield, J., Neef, N., et al. The relationship of glucokinase activator-induced hypoglycemia with arteriopathy, neuronal necrosis, and peripheral neuropathy in nonclinical studies. Toxicol. Pathol. 42(4), 696-708 (2014).

    2. Pffefferkorn, J.A., Guzman-Perez, A., Oates, P.J., et al. Designing glucokinase activators with reduced hypoglycemia risk: Discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus. Medchemcomm. 2, 828-839 (2011).